<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="323">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704534</url>
  </required_header>
  <id_info>
    <org_study_id>662507</org_study_id>
    <secondary_id>2011-002091-16</secondary_id>
    <nct_id>NCT01704534</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa</brief_title>
  <acronym>HiTS</acronym>
  <official_title>A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ustekinumab is effective in the treatment
      of moderate to severe hidradenitis suppurativa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label prospective study is performed to investigate the effectiveness and safety of
      ustekinumab in hidradenitis suppurativa. Twenty patients will be included. They will receive
      ustekinumab 45 or 90 mg on weeks 0-4-16-28. Patients will be followed up untill week 40.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Sartorius score</measure>
    <time_frame>76 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical response is defined as an improvement of the Sartorius score of at least 50%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28</description>
    <arm_group_label>Ustekinumab</arm_group_label>
    <other_name>Stelara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Hidradenitis suppurativa Hurley stage II or III

          -  No response to conventional local and oral antibiotics, or immunnesuppressive
             medication, or TNF-alpha inhibitors or surgery

          -  The patient has to be able to complete a dutch questionnaire

          -  Informed consent must be obtained

        Exclusion Criteria:

          -  Not able to complete a Dutch questionnaire

          -  Pregnancy or breast feeding

          -  Active hepatitis B or C infection, HIV or tuberculosis

          -  Treatment with biologics or other immunosuppressive medicine in the previous 3 months

          -  Malignancies in the last 10 years with the exception of basal cell carcinoma

          -  Demyelinating disorders

          -  Heart failure

          -  Known allergy to ustekinumab or to its preservatives

          -  Live vaccins in the next 3 months Sever liver or renal failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Horváth, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 12, 2015</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>Barbara Horváth, Principal Investigator</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Hidradenitis suppurativa</keyword>
  <keyword>Acne ectopica</keyword>
  <keyword>Inverse acne</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>Stelara</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
